NovaBridge Biosciences (NBP) Accounts Payables (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Accounts Payables data on file, last reported at $16.8 million in Q4 2025.

• Quarterly Accounts Payables rose 123.35% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.8 million (up 123.35% YoY) and the FY2025 annual result came in at $16.8 million, up 123.35% from the prior year.
• Accounts Payables climbed to $16.8 million in Q4 2025 per NBP's latest filing, from $7.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $99.3 million in Q4 2022 and bottomed at $7.5 million in Q4 2024.
• The 5-year median for Accounts Payables is $49.7 million (2023), against an average of $53.2 million.
• The widest annual swing landed in 2024, when Accounts Payables sank 84.84%; it then jumped 123.35% in 2025.
• Tracing NBP's Accounts Payables over 5 years: stood at $92.8 million in 2021, then climbed by 7.05% to $99.3 million in 2022, then sank by 49.99% to $49.7 million in 2023, then slumped by 84.84% to $7.5 million in 2024, then jumped by 123.35% to $16.8 million in 2025.
• Per Business Quant, the three latest NBP Accounts Payables figures stand at $16.8 million (Q4 2025), $7.5 million (Q4 2024), and $49.7 million (Q4 2023).

Peer Comparison